GlassScriptPhysician profile
Brittney Schumann
NPI 1841635851
$2,970.91
in general payments reported to CMS, 2019-2025
24 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2020: $204 · 2021: $602 · 2022: $641 · 2023: $646 · 2024: $277 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $66.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.37 |
| Education | $66.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $708.91 | 2019-2025 | Botox, Liletta, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $484.18 | 2022-2025 | |
| Allergan, INC. | $325.77 | 2019-2021 | |
| Therapeuticsmd, INC. | $168.00 | 2019-2022 | |
| Astellas Pharma US INC | $165.32 | 2022-2025 | Veozah, Myrbetriq |
| Agile Therapeutics, INC. | $136.62 | 2021-2023 | Twirla |
| Millicent US INC | $122.28 | 2023-2025 | Femring, Intrarosa |
| Exeltis, USA INC. | $108.35 | 2021-2025 | Slynd |
| Myovant Sciences INC. | $104.41 | 2021-2022 | |
| Avion Pharmaceuticals | $99.16 | 2019-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $98.09 | 2023-2025 | Myfembree, Gemtesa |
| Pfizer INC. | $83.89 | 2024-2025 | |
| Organon LLC | $82.76 | 2022-2024 | Nexplanon |
| Shield Therapeutics INC | $80.44 | 2023-2025 | Accrufer |
| Coopersurgical, INC. | $53.43 | 2021-2025 | Paragard T 380a |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $39.66 | 2025 | Zurzuvae |
| Dexcom, INC. | $21.43 | 2025 | Dexcom G6 Transmitter |
| Axonics, INC. | $20.03 | 2021 | |
| Urovant Sciences INC | $17.77 | 2021 | |
| Lupin INC. | $14.14 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.80 | 2021 | |
| Mission Pharmacal Company | $11.93 | 2021 | |
| Aspira Women'S Health INC | $10.54 | 2024 | Ova1 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney Schumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.